Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dysmenorrhea Clear all
Completed Phase 4 Interventional Results available

Examining the Role of Improved NSAID Management in Treating Dysmenorrhea and Bladder Pain

NCT03697720
View directory record Official record
Conditions
Dysmenorrhea, Pain
Interventions
Naproxen
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Jul 21, 2026, 7:41 PM EDT
Recruiting Not applicable Interventional

Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups

NCT06974773
View directory record Official record
Conditions
Endometriosis
Interventions
NettleEndo, Sham NettleEndo Device
Device
Lead sponsor
Samphire Group, Inc.
Industry
Eligibility
22 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study of Acupoint Injection for Primary Dysmenorrhea

NCT00995917
View directory record Official record
Conditions
Dysmenorrhea, Pain, Menstrual
Interventions
Vitamin K acupoint injection, Saline Injection
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept

NCT00963053
View directory record Official record
Conditions
Primary Dysmenorrhea
Interventions
VA111913 TS and placebo
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Peoria, Arizona • Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

NCT00196365
View directory record Official record
Conditions
Dysmenorrhea
Interventions
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, levonorgestrel/EE 0.15/0.03 mg tablets and placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigation Into the Efficacy of a Botanical Supplement to Provide Period Relief

NCT05845970
View directory record Official record
Conditions
Menstrual Pain, Premenstrual Syndrome
Interventions
Pamprin Botanicals, Pamprin Botanicals + Pamprin Menstrual Pain Relief
Other · Combination Product
Lead sponsor
Focus Consumer Healthcare
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess the Effect of My Happy Flo on Alleviating Period Symptoms and Heavy Flows.

NCT06522672
View directory record Official record
Conditions
Menstrual Cramps, Women's Health, Fatigue
Interventions
My Happy Flo
Dietary Supplement
Lead sponsor
My Happy Flo
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jul 21, 2026, 7:41 PM EDT
Not listed Phase 2 Interventional

Logan Basic and Dysmenorrhea

NCT00740818
View directory record Official record
Conditions
Menstrual Distress (Dysmenorrhea)
Interventions
No Intervention, Sham Logan Basic Adjustment, Logan Basic adjustment
Other · Procedure
Lead sponsor
Logan College of Chiropractic
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 24, 2008 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

NCT03213457
View directory record Official record
Conditions
Endometriosis
Interventions
Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
188
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect on Primary Dysmenorrhea

NCT00909857
View directory record Official record
Conditions
Primary Dysmenorrhea
Interventions
Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ethinyl estradiol, Levonorgestrel (Miranova), Placebo Match to SH T00658ID, Placebo Match to SH D593B
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 50 Years · Female only
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
10
States / cities
Tucson, Arizona • San Diego, California • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2015 · Synced Jul 21, 2026, 7:41 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

NCT03986944
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
107
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

NCT00318500
View directory record Official record
Conditions
Dysmenorrhea, Dyspareunia, Endometriosis, Pelvic Pain
Interventions
ERB-041
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
49
States / cities
Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2007 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Placebo-Controlled Study to Evaluate the Effects of a Gummy and Capsule Supplement on Symptoms of Premenstrual Syndrome

NCT06763809
View directory record Official record
Conditions
PMS, Menstrual Cramp, Mood Change
Interventions
PMS Capsule, Capsule Placebo, PMS Gummy, Gummy Placebo
Dietary Supplement
Lead sponsor
Semaine Health
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03654274
View directory record Official record
Conditions
Endometriosis
Interventions
Relugolix, Estradiol/norethindrone acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
60
States / cities
Andalusia, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Jul 21, 2026, 7:41 PM EDT
Not listed Phase 3 Interventional

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

NCT00458458
View directory record Official record
Conditions
Endometriosis, Dysmenorrhea, Dyspareunia
Interventions
Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Jul 21, 2026, 7:41 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Women's Health Study: From Adolescence to Adulthood

NCT01738204
View directory record Official record
Conditions
Pelvic Pain, Endometriosis, Dysmenorrhea, Infertility
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years to 60 Years · Female only
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jul 21, 2026, 7:41 PM EDT
Not listed Phase 2 Interventional

Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea

NCT04091789
View directory record Official record
Conditions
Dysmenorrhea, Headache, Migraine, Fatigue, Nausea, Mood Disturbance
Interventions
Pure Femme Tablets
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sterling Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impacts of Static Magnetic Fields on Dysmenorrhea Pain

NCT04539691
View directory record Official record
Conditions
Period Pain
Interventions
Magnet
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

NCT02778399
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, OBE2109
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
71
States / cities
Chandler, Arizona • Scottsdale, Arizona • Arcadia, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Jul 21, 2026, 7:41 PM EDT
Terminated Phase 3 Interventional Results available

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain

NCT04372121
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
23
States / cities
Little Rock, Arkansas • Norwalk, California • Greenwood Village, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jul 21, 2026, 7:41 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain

NCT03343067
View directory record Official record
Conditions
Endometriosis
Interventions
elagolix, estradiol/norethindrone acetate (E2/NETA)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Phase 3 Interventional

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03204318
View directory record Official record
Conditions
Endometriosis Related Pain
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
43
States / cities
Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Jul 21, 2026, 7:41 PM EDT
Recruiting Not applicable Interventional

Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)

NCT07337902
View directory record Official record
Conditions
Crohn's Disease (CD), Dysmenorrhea Primary
Interventions
Acetaminophen, Ibuprofen
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Mechanistic Characterization of Uterine Pain

NCT04145518
View directory record Official record
Conditions
Dysmenorrhea (Disorder), Dysmenorrhea Primary, Dysmenorrhea Secondary, Endometrial Diseases, Leiomyoma, Fibroid Uterus
Interventions
Naproxen Sodium
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 21, 2026, 7:41 PM EDT